Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
453.70    -5.90 (-1.28%)
Bid:
454.70
Ask:
454.90
Spread: 0.20 (0.044%)
Market Cap: £5.65b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

Disposal

6 Jun 2022 07:00

RNS Number : 6934N
Melrose Industries PLC
06 June 2022
 

3 June 2022

MELROSE INDUSTRIES PLC

 

SALE OF ERGOTRON

 

Sale of Ergotron

Melrose Industries PLC ("Melrose", the "Company" or the "Group") has entered into an agreement to sell its Ergotron business ("Ergotron"), to funds managed by The Sterling Group ("Sterling") for total consideration of approximately $650 million (c.£520 million), payable in cash on completion (the "Disposal"). Ergotron is a leading designer, manufacturer and distributor of ergonomic products for use in a variety of working, learning and healthcare environments, with gross assets (mostly goodwill) as at 31 December 2021 of £617 million and 2021 adjusted operating profit of £58 million (2021 EBITDA £62 million). 

Completion of the Disposal is expected to occur in the third quarter of 2022 ("Completion") and is conditional upon customary US antitrust approvals. On or before Completion, Melrose will announce how it intends to use the net proceeds from the Disposal. 

 

Successful execution of Melrose's strategy for Nortek

Having sold the Nortek Air Management and Nortek Control businesses last year, Ergotron is the last of the businesses remaining from the Nortek Inc acquisition in 2016. On Completion, Melrose will have more than doubled shareholders' initial investment, whilst transforming the Nortek businesses themselves.

Refocusing them away from unprofitable work, Melrose made the significant investment necessary to implement operational best practices, increase R&D, develop new products and build stronger customer relationships. These actions resulted in an almost doubling of adjusted operating margins and ensured each business remained highly cash generative, with over $1 billion generated during Melrose ownership.

This strong support and appropriate investment under Melrose ownership unlocked the potential of all the Nortek businesses and set them on the path for further success under new owners for the next stage of their development. 

 

Simon Peckham, Chief Executive of Melrose, today said:

"The sale of Ergotron is the final step in our Nortek ownership cycle, capping what has been a very successful acquisition for Melrose shareholders. We will have more than doubled shareholders' equity investment in Nortek and have transformed the businesses themselves. Our attention now remains firmly on achieving the same result for the current Group." 

 

Enquiries:

Investor Relations:

+44 (0) 7974 974690

ir@melroseplc.net

 

Montfort Communications - Financial PR:

+44 (0) 20 3514 0897

Nick Miles miles@montfort.london

+44 (0) 7739 701634

Charlotte McMullen mcmullen@montfort.london

+44 (0) 7921 881 800

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISBCGDLXXGDGDU
Date   Source Headline
19th Jun 20237:00 amRNSHolding(s) in Company
16th Jun 20234:45 pmRNSDirectorate Change
16th Jun 20231:30 pmRNSHolding(s) in Company
14th Jun 20236:19 pmRNSDirector/PDMR Shareholding
13th Jun 20234:50 pmRNSHolding(s) in Company
9th Jun 202310:00 amRNSHolding(s) in Company
8th Jun 20231:15 pmRNSResult of AGM
2nd Jun 202310:30 amRNSHolding(s) in Company
18th May 20235:15 pmRNSDirector/PDMR Shareholding
18th May 20234:02 pmRNSDirector/PDMR Shareholding
17th May 20231:00 pmRNSCapital Markets Event & New 2025 Guidance
15th May 20237:00 amRNSHolding(s) in Company
11th May 20235:15 pmRNSHolding(s) in Company
10th May 20237:00 amRNSTrading Update & New Guidance
5th May 20237:00 amRNSHolding(s) in Company
4th May 20237:00 amRNSHolding(s) in Company
27th Apr 202311:05 amRNSHolding(s) in Company
25th Apr 20234:35 pmRNSAnnual Report and Notice of Annual General Meeting
21st Apr 20234:00 pmRNSPost-Offer Undertakings Announcement
20th Apr 202312:20 pmRNSHolding(s) in Company
20th Apr 202311:55 amRNSDirector/PDMR Shareholding
20th Apr 20238:14 amRNSCompletion of the demerger of Dowlais
18th Apr 202311:30 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSDirector Declaration
13th Apr 20235:30 pmRNSMelrose Industries
3rd Apr 20237:00 amRNSHolding(s) in Company
31st Mar 20234:00 pmRNSConfirmation of Post-Offer Undertakings
30th Mar 202311:45 amRNSResults of General Meeting
17th Mar 20235:15 pmRNSDirector Declaration
16th Mar 20232:00 pmRNSSecond Interim Dividend - Payment Date
6th Mar 20234:15 pmRNSHolding(s) in Company
3rd Mar 20234:10 pmRNSPublication of a Prospectus
3rd Mar 20234:00 pmRNSCirc re. Demerger Proposal
2nd Mar 20237:00 amRNSFinal Results
17th Feb 20235:00 pmRNSDirector Declaration
31st Jan 20239:45 amRNSHolding(s) in Company
20th Jan 202312:30 pmRNSHolding(s) in Company
19th Jan 20237:00 amRNSTrading Update & Capital Markets Event
9th Jan 20237:00 amRNSHolding(s) in Company
15th Dec 20227:00 amRNSCapital Markets Event
16th Nov 20223:00 pmRNSDirector/PDMR Shareholding
15th Nov 20227:00 amRNSTrading Statement
4th Nov 20225:30 pmRNSDirector Declaration
31st Oct 20227:00 amRNSHolding(s) in Company
27th Oct 20225:37 pmRNSHolding(s) in Company
26th Oct 20225:00 pmRNSDirector/PDMR Shareholding
21st Oct 20229:45 amRNSHolding(s) in Company
17th Oct 20223:00 pmRNSHolding(s) in Company
10th Oct 20227:00 amRNSHolding(s) in Company
29th Sep 20224:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.